Partner
Ayman AlAbdallah is a partner at the San Francisco-based venture capital arm of Mubadala Capital where he is focused on investing in transformative healthcare technology, biotechnology, and deeptech companies. He is also a Co-founder and the Chief Financial and Operations Officer at Salma Health. Companies he has backed include Innovaccer, Capital Rx, Iambic AI, Color, Owkin, Exscientia (EXAI), Neumora (NMRA), Recursion (RXRX), Vir Biotechnology (VIR), and Vividion (acquired by Bayer), among others. He currently serves as a director or observer on the boards of Iambic Therapeutics, Georgiamune, Tahoe Therapeutics, Collective Health, Owkin, Unlearn AI, and Precision Neuroscience.